Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

New research has uncovered a built-in resistance mechanism to antibody–drug conjugates in some breast cancers and identified ...

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising effect in patients with active brain metastases of ...

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising ...

Health Canada has granted a Notice of Compliance (NOC) for Enhertu® (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class of therapeutics called ...

Shimadzu Asia Pacific joins the global celebration of Shimadzu Corporation's 150th anniversary, marking a century and a half ...

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: Daiichi Sankyo Company, in collaboration ...

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: Daiichi Sankyo Company, in collaboration ...

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...

Researchers present an overview of treatment and management strategies for patients with HR+/HER2+ breast cancer, including common adverse effects.